Tavo Biotherapeutics
Develops novel therapeutics for glaucoma and retinal diseases
$17MSeries A
Role not disclosedPB
Pureos Bioventures
pureosbio.com ↗Activity from announced rounds
Activity in this selectionSeries A
Pureos Bioventures invests in private drug-development companies, with an emphasis on new biological medicines and drug formats.
Venture capital for therapeutic development
Pureos Bioventures backs private companies developing new medicines for serious diseases. Its stated investment focus emphasizes biological drugs and new drug formats. The team combines venture-investment experience with operating, clinical and company-building backgrounds, supporting businesses whose development programs are grounded in scientific research.
Activity recorded by RoundOS
RoundOS records Pureos participation in Tavo Biotherapeutics, NovaGo Therapeutics and AnaCardio. These events span eye disease, central nervous system disorders and heart failure. They show the financings currently covered in this database; the firm’s own website lists a broader portfolio across multiple therapeutic areas.
Sources
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $17M 1 disclosed · full round size, not this investor’s share